Gerlach B, Meinhardt M, Kas MJH. Implementation of the EQIPD Quality System. J Neurosci Methods. 2024 405:110084. Epub 2024 Feb 23.
Gründer G, Brand M, Mertens L, Jungaberle H, Kärtner L, Scharf DJ, Spangemacher M, Wolff M. Treatment with psychedelics is psychotherapy: beyond reductionism. Lancet Psychiatry. 2024 11(3):231-236. Epub 2023 Dec 12.
Habelt B, Afanasenkau D, Schwarz C, Domanegg K, Kuchar M, Werner C, Minev IR, Spanagel R, Meinhardt M, Bernhardt N. Prefrontal electrophysiological biomarkers and mechanism-based drug effects in a rat model of alcohol addiction. Transl Psychiatry. 2024 14(1):486.
Hart XM, Spangemacher M, Defert J, Uchida H, Gründer G. Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants. Ther Drug Monit. 2024 46(2):155-169.
Hart XM, Spangemacher M, Uchida H, Gründer G. Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics. Ther Drug Monit. 2024 46(1):16-32. Epub 2023 Nov 27.
Lense XM, Hiemke C, Funk CSM, Havemann-Reinecke U, Hefner G, Menke A, Mössner R, Riemer TG, Scherf-Clavel M, Schoretsanitis G, Gründer G, Hart X. Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis. Psychopharmacology (Berl). 2024 241(2):275-289. Epub 2023 Oct 19.
Spangemacher M, Mertens L, Färber LV, Jungaberle A, Jungaberle H, Gründer G. Psilocybin as a Disease-Modifying Drug—a Salutogenic Approach in Psychiatry. Dtsch Arztebl Int. 2024 121(26):868-874. Epub 2024 Dec 27.
Wolff M, Evens R, Mertens LJ, Schmidt C, Beck J, Rutrecht H, Cherniak AD, Gründer G, Jungaberle H. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ). J Psychopharmacol. 2024 38(5):432-457. Epub 2024 May 14.
Wong DF, Chand GB, Caito N, Eramo A, Grattan VT, Hixon MS, Nicol G, Lessie E, Prensky Z, Kuwabara H, Tian L, Valenta I, Schindler TH, Gründer G, Vaino AR. PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement. Neuropsychopharmacology. 2024 50(2):372-377. Epub 2024 Oct 16.